Navigation Links
Navitas Names Dr. Dean Gesme as Medical Director
Date:10/17/2007

DENVER, Oct. 17 /PRNewswire/ -- Navitas Cancer Rehabilitation Centers of America, Inc. (Navitas), the market leader in providing integrated and comprehensive cancer rehabilitation services, is pleased to announce the appointment of Dean H. Gesme, Jr., M.D. as Corporate Medical Director.

In addition to currently providing care as a medical oncologist in the Minneapolis/St. Paul area, Dr. Gesme has served as the Past-Chair of the National Coalition for Cancer Survivorship and is Past-Chair of the Clinical Practice Committee of the American Society of Clinical Oncology. He has been the Oncology Representative on the AMA CPT Advisory Panel dealing with physician coding, and payment issues. Dr. Gesme is board certified in Internal Medicine, Medical Oncology, and Medical Management. Dr. Gesme attended medical school at the University of Iowa and completed his residency training in Internal Medicine in San Francisco and his fellowship in Medical Oncology at the University of Minnesota.

"Navitas has a tremendous opportunity to serve cancer survivors and Dr. Gesme is perfectly suited to provide medical leadership to this vision," shared Paul Barnes, Ph.D., President and CEO for Navitas. "Dean has devoted his career to the patient advocacy community as well to the treatment of cancer patients. We are fortunate to have him join our management team at Navitas.

"I have been impressed by the clinical basis of the cancer rehabilitation program at Navitas," Dr. Gesme stated. "I look forward to the day where rehabilitation services for cancer patients are as much the standard of care as is true for cardiac and other areas of medicine. Cancer patients deserve no less. I look forward to contributing to the clinical research efforts at Navitas to make that happen."

About Navitas Cancer Rehabilitation Centers of America

Founded in 2003, Navitas Cancer Rehabilitation Centers of America (http://www.navi
'/>"/>

SOURCE Navitas Cancer Rehabilitation Centers of America
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6